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ABSTRACT
Ovarian cancer is the leading cause of death of all gynecologic tumors, associated 
with widespread peritoneal dissemination and malignant ascites. Key to this is the 
ability to form multicellular spheroids (MCS); however, the tumor-specific factors that 
regulate MCS formation are unclear. p70 S6 kinase (p70S6K), which is a downstream 
effector of phosphatidylinositol 3-kinase/Akt, is frequently constitutively active in 
ovarian carcinoma. Here we identify p70S6K as a vital regulator of MCS formation. We 
also uncover a new mechanism of p70S6K function as a component of the microRNA 
biogenesis machinery in this process. We show that p70S6K phosphorylates, and 
inhibits the interaction of tristetraprolin (TTP) and Dicer that promotes the expression 
of a subset of miRNAs, including the maturation of miR-145. Twist and Sox9 are 
two divergent targets of miR-145, thereby enhancing N-cadherin, but not other 
cadherin, expression and MCS formation. Activating miR-145 suppresses ovarian 
tumor growth and metastasis in an orthotopic xenograft mouse model. Meta-analysis 
in the Oncomine database reveals that high p70S6K and low TTP levels are associated 
with ovarian tumor progression. These results define a critical link between p70S6K, 
miRNA maturation, and MCS formation that may underlie poor clinical outcome of 
ovarian cancer patients for developing novel therapeutic strategies.
INTRODUCTION
Ovarian cancer is the leading cause of death 
from gynecologic cancers [1]. The majority of cases 
(70%) are diagnosed after the disease has already 
metastasized with widespread peritoneal dissemination 
and malignant ascites. Several lines of evidence suggest 
that multicellular spheroids (MCS) play an important role 
in the biology of ovarian cancer. First, ovarian cancer 
cells in peritoneal ascites exist as MCS (30-200 μm) [2]. 
Second, MCS can readily attach to and disaggregate on 
the peritoneum [3, 4]. Third, MCS recapitulate aggressive 
tumorigenesis when transplanted into mice [5]. Fourth, 
ovarian cancer cells routinely propagating in vitro as 
MCS may generate a subpopulation of cancer stem/
tumor-initiating cells, which are highly neoplastic [6–8]. 
These MCS are also particular critical in addressing the 
challenge of treating ovarian cancer in which current 
therapies are ineffective (5-year survival <25%). 
However, the factors that regulate MCS formation are 
largely unknown.
There is growing evidence supports the importance 
of p70 S6 kinase (p70S6K), a downstream effector of 
PI3K/Akt, in ovarian cancer [9]. p70S6K activation 
occurs significantly more often in ovarian tumors than 
in benign or borderline lesions, and that constitutive 
activation of p70S6K correlates with aggressive malignant 
phenotypes [10]. Although it was originally described as 
being predominantly involved in cell growth, we have 
provided the first evidence for a role of p70S6K in other 
aspects of tumor progression, such as metastasis [10–12]. 
However, it is still not known whether p70S6K affects MCS 
formation, although this is a key mechanism of ovarian 
cancer metastasis. The ribosomal protein S6 was the 
first and most well-known substrate of p70S6K. However, 
despite the diverse process controlled by p70S6K, only few 
substrates are known.
MicroRNAs (miRNAs) are small non-coding 
RNAs that have recently emerged as fundamental 
posttranscriptional regulators of target gene expression. 
Although first identified in c. elegans, miRNAs are 
now known to be expressed in most organisms and 
aberrant miRNA expression has been implicated in the 
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pathogenicity of human cancers [13]. Of equal importance 
as transcriptional regulation, the processing of premature 
miRNAs is a critical rate-limiting step in miRNA 
biogenesis that controls mature miRNA turnover. Primary 
(pri-) miRNAs are processed into precursor (pre-) miRNAs 
by the dsRNA-specific ribonulease Drosha, whereas pre-
miRNAs are cleaved to produce mature miRNAs by Dicer 
[14, 15]. While detailed insight has been gained into their 
target genes, little is known about signaling mechanisms 
controlling miRNA biogenesis, particularly those that 
relate to disease.
Here we show for the first time that p70S6K is a 
pivotal regulator of MCS formation. We also provide 
mechanistic insight that a unique aspect of the function 
of p70S6K by which it suppresses the maturation of miR-
145, which controls the turnover of two critical transcripts 
Twist and Sox9 in the regulation of N-cadherin through 
tristetraprolin (TTP)/Dicer-dependent pathway.
RESULTS
p70S6K promotes MCS formation
In addressing the factors that promote MCS 
formation, we considered the role of p70S6K, which is 
a key intracellular signaling mediator for the effects of 
multiple growth factors in the malignant ascites and is 
frequently hyperactive in human ovarian cancer [12]. 
Indeed, overexpression of the constitutively active 
p70S6K, (D3E-E389) was sufficient to robustly increase 
MCS formation (3.3-fold) (Figure 1A). Using a siRNA-
based silencing approach, p70S6K siRNA significantly 
suppressed MCS formation, establishing that p70S6K as 
an endogenous promoter of MCS formation in ovarian 
cancer (Figure 1B). A second p70S6K siRNA showed 
similar results (data not shown), and the nonspecific 
siRNA had no effect (Figure 1B).
Figure 1: p70S6K promotes MCS formation. A. CaOV-3 cells were transfected with pcDNA3 or constitutively active p70S6K construct 
(D3E-E389) or B. SKOV-3 cells were transfected with nonspecific (NS) siRNA or p70S6K siRNA for 72 hr. Total RNA was extracted and 
reverse transcription-PCR was performed using p70S6K sequence-specific primers. β-actin was included as a control. The band intensities 
were quantified by densitometric analysis and expression levels relative to that of β-actin were shown. The number of tumor spheres 
generated in CaOV-3 and SKOV-3 were photographed and counted. Bar = 100 µm. Results are presented as the mean ± SD and were 
analyzed using paired student’s t test. *P < 0.05; **P < 0.005, compared with pcDNA3 or NS siRNA.
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N-cadherin is the regulator of MCS phenotype 
upon p70S6K activation
Cadherins are major mediators of cell-cell adhesion 
[16]. To begin addressing whether cadherin has a role in 
MCS formation, the expression of E-, N-, and P-cadherin, 
which have key roles in ovarian tumor progression [17] in 
relation to their ability to form MCS was first examined. 
Western blot analysis demonstrated that N-cadherin was 
highly expressed in SKOV-3 and HEYA8 cells, both of 
which have been shown to most effectively form compact 
spheroids (Supplementary Figure S1A & S1B). CaOV-3 
and A2780 cells, which possess little or no N-cadherin, 
showed no MCS formation (Supplementary Figure S1A & 
S1B). Importantly, p70S6K was expressed at higher levels in 
SKOV-3 and HEYA8 cells, which exhibit physiologically 
higher endogenous levels of N-cadherin (Supplementary 
Figure S1A & S1B). It is worth noting that this seems to 
be independent of the endogenous expression of E- or 
P-cadherin (Supplementary Figure S1A & S1B). Of note, 
depletion of N-cadherin by the use of siRNA, in which 
reduced the levels of N-cadherin, but not the levels of 
E- or P-cadherin, inhibited the ability of SKOV-3 and 
HEYA8 cells to form MCS (Figure 2A). No inhibition 
was observed for nonspecific siRNA, confirming that 
the effect is N-cadherin specific (Figure 2A). Similarly, 
hindering N-cadherin engagement with a function-
blocking antibody also ablated MCS formation, whereas 
control IgG was without effect (Figure 2B). These results 
suggest that N-cadherin may have a dominant effect over 
other cadherins on MCS formation of ovarian cancer cells.
p70S6K increases N-cadherin expression via Twist 
and Sox9
To determine whether p70S6K mediates MCS 
formation via N-cadherin, we first overexpressed 
constitutively active p70S6K, D3E-E389. This resulted in 
an effective upregulation of N-cadherin (Figure 2C). 
Conversely, knocking down p70S6K clearly abolished 
the induction of N-cadherin (Figure 2D). Furthermore, 
inhibition of N-cadherin significantly suppressed MCS 
formation by D3E-E389 overexpression (Figure 2E), 
indicating also a functional correlation between p70S6K and 
N-cadherin in MCS formation.
N-cadherin is known to be activated through at 
least two transcriptional regulators, including Twist and 
Sox9 [18]. This is also relevant to the clinical situation 
that Twist and Sox9 are often elevated in malignant 
ovarian tumors and confer a poor outcome to the late 
stage ovarian cancer patient survival [19, 20]. Given the 
robust effects of p70S6K on N-cadherin, we investigated 
whether p70S6K regulates expression of these two genes 
(Twist and Sox9). As shown in Figure 3A, D3E-E389 
markedly induced an increase in Twist and Sox9 mRNA, 
which correlated with the upregulation of its target gene, 
N-cadherin (Figure 3A). In contrast, depletion of Twist 
and Sox9 through specific siRNAs led to repression of 
the D3E-E389-induced N-cadherin mRNA expression 
(Figure 3A). Furthermore, siRNA depletion of Twist and 
Sox9 inhibited MCS formation (Figure 3B), suggesting 
functional roles for them.
p70S6K activation stabilizes Twist and Sox9 
mRNAs
Since the increase of mRNA could result from 
either increased transcription or mRNA stability, this 
prompted us to investigate the cellular mechanisms 
underlying p70S6K regulation of Twist and Sox9 mRNAs. 
Interestingly, D3E-E389 was without effect on the induction 
of luciferase activity driven by Twist- and Sox9-promoter 
regions (Supplementary Figure S2). We next performed 
RNA decay analyses using actinomycin D. Twist mRNA 
t1/2 was prolonged in D3E-E389-expressing CaOV-3 cells 
(t1/2 ~ 7.6 h) by approximately 2-fold (Figure 4A). D3E-E389 
expression produced a similar stabilization of Sox9 mRNA 
(t1/2 ~ 7.5 h) (4.7-fold) (Figure 4B). These results suggest 
that p70S6K may interfere with the mRNA degradation 
pathway to stabilize Twist and Sox9 mRNAs, leading to 
their accumulation.
p70S6K directly targets miR-145 to increase Twist 
and Sox9 expression
Given the importance of p70S6K in mediating 
Twist and Sox9 mRNA half-lives, we were particularly 
interested in miRNAs that have been demonstrated to 
function in these processes [21]. To address this question, 
we employed a systematic approach to identify such 
miRNA regulators which should have the ability to 
bind the Twist and Sox9 mRNAs. We first compared 
the set of miRNAs predicted to target Twist and/or Sox9 
3’UTR using miRNAmap 2.0 which employs a variety 
of prediction databases (Target Scan program, miRanda 
algorithm, and RNAhybrid program). The analysis, 
followed by examination of the set of miRNAs known to 
be associated with ovarian cancer progression [22–24], 
revealed 17 miRNAs (let-7b, miR-10b, miR-105, miR-
127, miR-133a, miR-145, miR-147, miR-154, miR-199a, 
miR-199b, miR-214, miR-299, miR-302c, miR-331, 
miR-337, miR-376, miR-424) to target either Twist and/
or Sox9 mRNAs and also present at lower levels in the 
metastatic progression of ovarian cancer. Among these 
miRNAs, interestingly, only the expression of miR-145 
was significantly repressed by the constitutively active 
p70S6K and increased by the p70S6K siRNA as compared 
to their respective empty vector and nonspecific siRNA 
controls (Figure 5A). These results suggest that p70S6K 
promotes the expression of specific miRNAs.
In order to verify whether Twist and Sox9 are 
directly targeted by miR-145, we examined the effect of 
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Figure 2: Silencing of N-cadherin abolishes MCS formation. A. SKOV-3 or HEYA8 were transfected with nonspecific (NS) 
siRNA, E-cadherin siRNA, N-cadherin siRNA or P-cadherin siRNA. Expression of E-cadherin, N-cadherin and P-cadherin were assessed 
by Western blotting. β-actin was included as a loading control. The band intensities were quantified by densitometric analysis and expression 
levels relative to that of β-actin were indicated. The number of tumor spheres generated in were photographed and counted. B. SKOV-3 or 
HEYA8 cells were incubated with IgG or N-cadherin function blocking antibody for 72 hr. The number of tumor spheres generated was 
photographed and counted. C. CaOV-3 cells were transfected with pcDNA3 or constitutively active p70S6K (D3E-E389) or D. SKOV-3 cells 
were transfected with NS siRNA or p70S6K siRNA for 72 hr. Total RNA was extracted and reverse transcription-PCR was performed using 
N-cadherin sequence-specific primers. β-actin was included as a control. The band intensities were quantified by densitometric analysis and 
expression levels relative to that of β-actin are indicated. E. CaOV-3 cells were transfected with pcDNA3 or D3E-E389 in the presence of 
NS siRNA or N-cadherin siRNA for 72 hr. The number of tumor spheres generated was photographed and counted. Bar = 100 µm. Results 
are presented as the mean ± SD and were analyzed using paired student’s t test. **P < 0.005, compared with NS siRNA, IgG or pcDNA3.
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miR-145 on the expression of Twist and Sox9 through 
heterologous luciferase reporter assays. As shown, miR-
145 was able to repress the luciferase activity of reporter 
containing the 3’ untranslated regions (UTR) of both Twist 
and Sox9, revealing Twist and Sox9 to be directly targeted 
by miR-145 (Figure 5B). Consistent with the phenotypes 
of its target genes, addition of pre-miR-145 abrogated 
D3E-E389-mediated MCS formation, whereas addition of 
anti-miR-145 reversed the suppression of MCS formation 
resulting from p70S6K knockdown, indicating that miR-145 
is necessary for the promotion of MCS (Figure 5C). To 
investigate whether the potential regulation of miR-145 
Figure 3: p70S6K increases expression of Twist and Sox9 transcription factors. A. CaOV-3 transfected with pcDNA3 or 
constitutively active p70S6K (D3E-E389) in the presence of nonspecific (NS) siRNA or Twist siRNA or Sox9 for 72 hr. Total RNA was 
extracted and reverse transcription-PCR was performed using Twist, Sox9, and N-cadherin sequence-specific primers. The signal intensities 
were quantified by densitometric analysis and expression levels relative to that of β-actin are indicated. B. The number of tumor spheres 
generated was photographed and counted. Bar = 100 µm. Results are presented as the mean ± SD and were analysed using paired student’s 
t test. *P < 0.05; **P < 0.005, compared with pcDNA3 or NS siRNA.
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on Twist and Sox9 also correlated with MCS formation 
potential, we compared the levels of miR-145 with the 
expression levels of Twist and Sox9. We observed that 
SKOV-3 and HEYA8 showing little or no miR-145 also 
expressed high levels of Twist and Sox9 (Figure 5D). 
Expression of N-cadherin which determines the ability 
to form MCS was significantly more frequent in SKOV-3 
and HEYA8 than CaOV-3 (Figure 5E).
A specific role for Dicer microprocessor in miR-
145 turnover
To determine how p70S6K regulates miR-145 
expression, we assessed different aspects of miR-145 
expression in response to p70S6K. Despite the increases 
in mature miR-145 expression, no significant changes 
were observed in primary miR-145 levels following 
p70S6K siRNA as determined by RT-PCR (Figure 
6A). Furthermore, it has also been shown that its 
downregulation observed in various tumors is not due to 
DNA copy number loss [24, 25], suggesting that p70S6K 
may post-transcriptionally regulate miR-145 expression. 
One post-transcriptional mechanism by which p70S6K 
could possibly downregulate the levels of mature miR-
145 is by suppressing the maturation of miR-145. Previous 
reports have demonstrated that Dicer serves as a major 
regulator of the miRNA biogenesis machinery [26]. 
Knocking down Dicer clearly abolished the p70S6K siRNA-
mediated suppression of MCS formation (Figure 6B), 
suggesting a novel link between p70S6K and Dicer in MCS 
formation and warrants a closer examination into the 
mechanism through which p70S6K regulates Dicer.
p70S6K impairs the interaction of TTP with Dicer
We first examined the potential regulation of p70S6K 
on Dicer expression, but found no effect (Figure 6C), 
suggesting that p70S6K may regulate Dicer via its 
interacting partners. The recruitment of AU-rich RNA-
binding protein (ARE-BP), KH-type splicing regulatory 
protein (KSRP), to Dicer is critical for loading miRNA 
precursors onto the microprocessor complex and 
facilitating miRNA maturation from precursor to mature 
miRNAs [27]. However, we found no similar interaction 
between KSRP and Dicer upon p70S6K activation 
(Figure 6D). Thus we investigated whether other members 
of ARE-BPs may physically associate with Dicer. TTP 
displayed lower levels in the metastatic progression 
of ovarian cancer [28] albeit previously not known to 
interact with Dicer. Coimmunoprecipitation experiments 
showed that silencing of p70S6K significantly enhanced the 
interaction of TTP with Dicer (Figure 6D), suggesting that 
TTP can bind Dicer.
The miRNA destabilizing factor TTP is 
phosphorylated by p70S6K
Knockdown of TTP obtained using siRNA led to a 
more than 75% reduction in the steady-state level of miR-
145 (Figure 7A). Furthermore, Twist, Sox9, and N-cadherin 
mRNAs were stable in TTP siRNA-transfected cells 
Figure 4: p70S6K enhances Twist and Sox9 mRNA stabilities. A. CaOV-3 cells transfected with pcDNA3 or D3E-E389 were 
incubated with actinomycin D (ActD; 5 µg/ml) over a time course of 0, 2, 4, 8 and 24 hr. Total RNA was then extracted and reverse 
transcription-PCR was performed using Twist and B. Sox9 sequence specific primers. β-actin was included as an internal control. Results 
are presented as the mean ± SD.
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Figure 5: p70S6K decreases Twist and Sox9 mRNA turnover via suppression of miR-145. A. CaOV-3 cells were transfected 
with pcDNA3 or constitutively active p70S6K (D3E-E389) or SKOV-3 cells were transfected with nonspecific (NS) siRNA or p70
S6K siRNA 
for 72 hr. Total RNA was extracted and reverse transcription-PCR was performed using mature miR-145 sequence-specific primers. U6 
was included as an internal control. The signal intensities were quantified by densitometric analysis and the amounts were normalized for 
the amount of U6. B. CaOV-3 cells were transiently transfected with 0.5 µg of the luciferase reporter gene fused with Twist 3’UTR or 
Sox9 3’UTR and 15 ng of β-galactosidase plasmid for 72 hr. Luciferase and β-galactosidase activities were assayed, and the luciferase 
activity of each sample was normalized with β-galactosidase activity. C. CaOV-3 cells were transfected with pcDNA3 or D3E-E389 in the 
presence of NS miRNA or precursor miR-145 (pre-miR-145) or SKOV-3 were transfected with NS siRNA or p70S6K siRNA in the presence 
of NS miRNA or miR-145 inhibitor (anti-miR-145) for 72 hr. The number of tumor spheres generated was photographed and counted. Bar 
= 100 µm. D. CaOV-3, SKOV-3 and HEYA8 were cultured in non-adherent culture dish for 72 hr. Total RNA was extracted and reverse 
transcription-PCR was performed using sequence-specific primers to mature miR-145 (mat-miR-145). U6 was included as an internal 
control. E. Twist, Sox9, and N-cadherin sequence-specific primers. β-actin was included as an internal control. The signal intensities were 
quantified by densitometric analysis and the amounts were normalized for the amount of U6 or β-actin. Results are presented as the mean ± 
SD and were analyzed using paired student’s t test. *P < 0.05; **P < 0.005, compared with NS siRNA, pcDNA3 or NS miRNA.
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(Figure 7B). Importantly, knockdown of TTP significantly 
restored the decreased MCS formation mediated by 
knockdown of p70S6K (Figure 7C). Together, these results 
indicate that TTP is crucial in controlling miR-145 
maturation and, in turn, Twist/Sox9-mediated N-cadherin 
expression and MCS formation. The phosphorylation of 
RNA-binding proteins modulates their association with 
Dicer [29]. We further investigated whether p70S6K was 
able to phosphorylate TTP. Using PhosphoNet (www.
Phosphonet.ca/), a kinase substrate prediction database, 
TTP has been found to be a putative substrate for p70S6K 
(Figure 7D). Knockdown of p70S6K significantly reduced 
the phosphorylation of TTP while not empty vector control, 
as shown by anti-TTP immunoprecipitation following 
phospho-serine detection (Figure 7D), suggesting that 
p70S6K is a novel upstream regulator of the TTP.
p70S6K and its associated signaling in human 
ovarian carcinoma
To understand more about the clinical relationship 
between p70S6K and TTP levels in ovarian tumors, we 
used the publicly available datasets from Oncomine 
(available at: https://www.oncomine.org) to survey a 
large number of ovarian cancers. There was a significant 
inverse association between p70S6K and TTP levels, in 
Figure 6: p70S6K downregulates mature miR-145 but not primary miR-145. A. SKOV-3 cells were transfected with nonspecific 
(NS) siRNA or p70S6K siRNA for 72 hr. Total RNA was extracted and reverse transcription-PCR was performed using sequence-specific 
primers to primary miR-145 (pri-miR-145) and mature miR-145 (mat-miR-145). U6 was included as an internal control. The signal 
intensities were quantified by densitometric analysis and the amounts were normalized for the amount of U6. B. SKOV-3 cells were 
transfected with NS siRNA, p70S6K siRNA, or Dicer siRNA for 72 hr. The number of tumor spheres generated was photographed and 
counted. C. SKOV-3 cells were transfected with nonspecific (NS) siRNA or p70S6K siRNA for 72 hr. Total RNA was extracted and reverse 
transcription-PCR was performed using Dicer sequence-specific primers. β-actin was included as an internal control. The signal intensities 
were quantified by densitometric analysis and expression levels relative to that of β-actin are indicated. D. p70S6K siRNA-transfected 
SKOV-3 cells were immunoprecipitated with Dicer antibody. Rabbit serum was used as a control. The immunocomplex was resolved using 
Western blotting and detected with KSRP and TTP antibodies. Bar = 100 µm. Results are presented as the mean ± SD and were analyzed 
using paired student’s t test. *P < 0.05; **P < 0.005, compared with NS siRNA.
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Figure 7: TTP increases the level of mature miR-145. A. SKOV-3 cells were transfected with nonspecific (NS) siRNA or 
TTP siRNA over a time course of 4, 8, 16, 20 and 24 hr. Total RNA was extracted and reverse transcription-PCR was performed using 
sequence-specific primers to mature miR-145 (mat-miR-145). U6 was included as an internal control. The signal intensities were 
quantified by densitometric analysis and the amounts were normalized for the amount of U6. B. Reverse transcription-PCR was also 
performed using sequence-specific primers to Twist, Sox9 and N-cadherin. β-actin was included as an internal control. The signal 
intensities were quantified by densitometric analysis and expression levels relative to that of β-actin are indicated. C. SKOV-3 cells 
were transfected with NS siRNA, p70S6K siRNA or TTP siRNA for 72 hr. The number of tumor spheres generated was photographed 
and counted. D. In silico analysis of the TTP phosphorylation sites were performed using the Human Phosphosite Knowledgebase 
available at PhosphoNet (http://www.phosphonet.ca/). Phosphorylation sites with a Kinase Predictor score greater or equal to 350 
were indicated. p70S6K-stable knockdown SKOV-3 cells were immunoprecipitated with TTP antibody. Rabbit serum was used as 
a control. The immunocomplexes were resolved using Western blotting and detected by a phosphoserine antibody. Bar = 100 µm. 
Results are presented as the mean ± SD and were analyzed using paired student’s t test. *P < 0.05; **P < 0.005, compared with NS 
siRNA or p70S6K siRNA.
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which p70S6K was highly expressed in tumor samples 
whereas TTP was suppressed (Figure 8A). Next, we 
transplanted nonspecific miRNA and precursor miR-145 
MCS cells into the peritoneum of NOD/SCID mice to 
determine whether miR-145 activation actually produced 
a less malignant phenotype in vivo. The results showed 
that highly aggressive tumors with visible tumor masses 
growing on the omentum, mesenteries, and small bowels 
with developed ascites reflecting characteristics commonly 
displayed by ovarian cancer lesions were observed in 
mice transplanted with nonspecific miRNA (Figure 8B). 
In contrast, the number and the size of tumor nodules and 
ascites volume were substantially decreased by treatment 
with precursor miR-145 (Figure 8B). These studies 
suggest that p70S6K and its associated signaling may 
represent useful targets for the treatment of aggressive cell 
characteristics of ovarian cancer in vivo.
DISCUSSION
Metastatic progression requires effectors proteins 
associated with the same cellular phenotype to be 
coherently expressed. In recent years, posttranscriptional 
regulation has emerged as a robust regulation of 
coordinated gene expression and phenotype manifestation. 
The most studied of which is small noncoding miRNAs. 
In this study, we show for the first time that p70S6K, which 
is frequently hyperactive in human ovarian cancer [11], as 
a novel component of the miRNA biogenesis machinery, 
which governs post-transcriptional maturation of a subset 
of miRNAs, and that this regulation is important in 
effecting MCS formation.
As a key kinase in the control of target mRNA 
translation, p70S6K is logically considered to be a 
modulator of protein synthesis. Here we provide the first 
demonstration that p70S6K, a key kinase in the control of 
target mRNA translation, can regulate miRNA biogenesis. 
This role of p70S6K in the miRNA-generating complex 
regulation is one of the most important and exciting 
emerging paradigms, which may link its multiple facets 
of cell activities seen [10], and its therapeutic inhibition 
displays in vivo efficacy highlights the significance of 
p70S6K as a key promoter of ovarian metastatic progression.
The regulation of miRNA remains still largely 
unknown. Clearly, transcriptional regulation is an essential 
control. Alternatively, the posttranslational modification 
Figure 8: p70S6K and TTP expression in human ovarian cancers and miR-145 upregulation results in decreased cancer 
progression in vivo. A. Clinical data were retrieved from the TCGA Ovarian dataset which contains 594 samples available on Oncomine 
(https://www.oncomine.org). B. NOD/SCID mice were intraperitoneally injected with SKOV-3 cells transduced by nonspecific (NS) 
miRNA or precursor miR-145 (pre-miR-145). At the time of sacrifice, the peritoneal cavity was assessed for evidence of metastases. The 
metastatic lesions were excised and their total number was counted, and ascites volume was measured. Results are presented as the mean ± 
SD. *P < 0.05 compared with NS miRNA.
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of miRNAs, albeit less studied, has recently garnered 
much attention as an important regulatory mechanism of 
miRNA activities. Various kinases, such as p38 MAPK, 
Akt, and ATM have been shown to phosphorylate KSRP of 
the miRNA-generating complex at different residues and 
regulate its biological activities [30, 31]. This study is the 
first to demonstrate that TTP, an ARE-BP that has been 
widely studied for posttranscriptional gene regulation and 
miRNA biogenesis [27], is a substrate of p70S6K, adding 
p70S6K as a new member of posttranscriptional modulators 
of miRNAs, and TTP as a new protein interactor of Dicer. 
In accordance with our findings, while changes in the 
expression level of Dicer was not frequently observed 
in ovarian cancer tissues [24], TTP loss is found in 
many types of cancers including ovarian cancer and 
this downregulation correlates with increased metastatic 
potential and poor prognosis [28, 32–34]. Although it is 
possible that TTP may disrupt the global translation of all 
miRNAs, our existing data suggest that not all miRNAs 
are targets of TTP. Likewise, a G-rich motif in precursor 
miRNAs has been identified as a critical regulatory 
element in KSRP, an ARE-BP-mediated miRNA 
maturation, suggesting regulation specificity of ARE-BP 
on miRNA maturation [35].
Little is known about the regulation of N-cadherin. 
Here we show for the first time that miR-145 divergently 
targets Twist and Sox9 and comprise a coordinated 
network that maximally enhances N-cadherin signaling. 
Consistently, seeding regions of miR-145 has been 
identified in 461-488 of the Twist 3’UTR (NG_008114.1) 
and 265-289 of the Sox9 3’UTR (NG_012490.1). The 
simultaneous targeting of multiple genes for metastasis 
promotion by a single metastasis suppressor miRNA may 
explain the dramatic effects observed [36], highlighting 
the significance of miR-145 as a key tumor suppressor 
of ovarian cancer progression. Indeed, miR-145 is one of 
the most frequently studied miRNAs detected in human 
cancers, and it has been validated to be downregulated 
in ovarian cancer [22]. miR-145 downregulation is 
associated with ovarian cancer progression and that low 
miR-145 expression correlates with poor survival [37]. 
It is also relevant to the clinical situation that Twist and 
Sox9 are often elevated in malignant ovarian tumors and 
Twist expression confers a poor outcome to the late stage 
ovarian cancer patient survival [19, 20].
The importance of miRNAs in cancer biology 
has opened avenues for drug development based on the 
inhibition of oncomiRs or replacement of suppressor 
miRNAs [38, 39]. The advantage of using miRNA 
approaches is based on its ability to simultaneously target 
multiple genes that may be involved in coregulating 
a given function. Traditional gene therapy is hindered 
by inefficient delivery of large encoding gene into the 
nucleus. On the contrary, miRNAs are small in size and 
active in cytoplasm [40]. Liposome-based nano-sized 
carrier-mediated miRNA delivery constitutes a promising 
nanomedicine approach in cancer therapy. Indeed, the 
safety and efficacy of miR-34 liposomal injection is 
undergoing Phase I clinical trials on liver, lung, renal 
cell carcinomas, and other hematologic malignancies 
(NCT01829971, https://clinicaltrials.gov/ct2/show/ NC
T01829971?term=NCT01829971&rank=1). The closed 
space of the peritoneal cavity may offer an advantage for 
gene transfer in that the therapeutic genes can be sensitive 
and specific to the target cells.
Deregulation of p70S6K signaling frequently 
occurs in many human cancers, and it appears to play 
an important role in their progression. For example, 
active p70S6K-expressing breast cancer has a worse 
prognosis [41]. Furthermore, p70S6K overexpression 
in breast, colon, liver, and ovarian tumors are found 
to be related to aggressive malignant phenotypes [11, 
42–44], suggesting that the role of p70S6K in MCS that 
we propose in ovarian cancer may be extended to other 
tumor cell types and thereby p70S6K could be an attractive 
target for therapeutics. Despite the fact that many PI3K 
pathway inhibitors have been developed, the clinical 
trials with these drugs have not been promising due to 
crosstalk with multiple pathways and the presence of 
potent feedback loops [45]. Targeting p70S6K may thus 
represent a potential therapeutic advantage over current 
PI3K inhibitors, which might prove to be more effective 
and specific while minimizing toxicity. Moreover, 
the addiction of many tumors to the pathway provides 
a rationale for PI3K/Akt target, particularly p70S6K, 
exploitation.
In summary, we have established a novel regulatory 
link between p70S6K and miRNA biogenesis that not 
only highlights a new mechanism through which p70S6K 
functions to establish its pro-tumor regimen but also 
defines the MCS properties. These findings introduce a 
new dimension to our existing knowledge of the regulation 
of miRNA machinery and signaling molecules that 
remains to be explored by which can be exploited as more 
precise targets for therapy. The prominent role of p70S6K in 
a broad range of human cancers suggests that its targeting 
may have key roles, not only in ovarian cancer, but also 
in other tumors.
MATERIALS AND METHODS
Cell culture and treatments
The human epithelial ovarian cancer cell lines 
SKOV-3, CaOV-3, and A2780 were gifts from Dr. N. 
Auersperg (University of British Columbia, Vancouver, 
B. C., Canada). HEYA8 was a gift from Dr. J. Liu (MD 
Anderson Cancer Center, Houston, TX). Cells were 
routinely grown in medium 199:MCDB 105 (1:1) (Sigma, 
St. Louis, MO) with 10% fetal bovine serum (Hyclone, 
Logan, UT) and 1% penicillin-streptomycin mixture 
(Invitrogen, Carlsbad, CA) in a humidified 95% air, 
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5% CO2 incubator at 37°C before experiments. MCS 
were generated by liquid overlay method [46]. Briefly, 
5,000 cells/ml were plated into dishes coated with 0.5% 
agarose (Invitrogen, Carlsbad, CA) (non-adherent culture 
conditions) for 72 h after treatment. The number of MCS 
generated with ≧100 μm diameter was counted. Mature 
miR-145 mimic were purchased from Ambion (Austin, 
TX). Synthetic oligos, mock with no homology to 
human genome, were used as a negative control. p70S6K 
siRNA, Twist siRNA, Sox9 siRNA were acquired from 
Dharmacon (Lafayette, CO). miRNA or siRNA duplex 
were transfected into cells by using Lipofectamine 2000 
according to the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA).
Measurement of mRNA stability
The half-life of Twist and Sox9 mRNAs were 
determined using actinomycin D chase experiments, 
following a standard protocol described elsewhere [47]. 
Briefly, actinomycin D was added to a final concentration 
of 5 μg/ml to block further transcription. At 0, 2, 4, 8, and 
24 hr after actinomycin D treatment, the cells were 
harvested, and mRNA was quantified by PCR as described 
above. The percentages of mRNA over time before and 
after the addition of actinomycin D were determined.
Reverse transcription-polymerase chain reaction
Total RNA was isolated by Trizol (Invitrogen, 
Carlsbad, CA). For detecting miR-145 levels, RNA 
was reversed transcribed to cDNA by TaqMan 
miRNA assays (Applied Biosystems, Foster City, 
CA) using specific stem-loop reverse transcription 
primer (5’-GTTGGCTCTGGTGCAGGGTCCGAGG
TATTCGCACCAGAGCCAACAGGAT-3). The ex-
pression levels of mature miR-145 was quantified 
by PCR using sequence specific primers (Forward: 
5’-CGGCAGGTCAAAAGGGTCCT-3’; Reverse: 5’-TG 
CAGG GTCCGAGGTATTCG-3’). Endogenous U6 small 
nuclear RNA levels were determined simultaneously for 
normalization.
miRNA target prediction
To define potential upstream regulators of Twist and 
Sox9, we matched candidate miRNAs that were predicted 
by using miRNAMap 2.0 (available at http://mirnamap.mbc.
nctu.edu.tw/) which employs 3 publicly available algorithms, 
miRanda (http://www.microrna.org/microrna/home.do), 
TargetScan (http://www. targetscan.org/), and RNA hybrid 
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid).
Western blot analysis
Cell lysates (20 μg protein each) were separated 
by 7.5% SDS-polyacrylamide gel electrophoresis and 
transblotted onto nitrocellulose membrane (Bio-Rad). 
The membrane was blocked with 5% nonfat dry milk and 
incubated with anti-phospho-p70S6K (Thr389) (1:1,000) 
(Cell Signaling), anti-Twist (1:1,000) (Santa Cruz), 
anti-Sox9 (1:1,000) (Abcam), anti-N-cadherin (1:1,000) 
(Zymed), anti-E-cadherin (1:1,000) (BD Transduction 
Laboratories) in phosphate-buffered saline containing 
0.1% Tween 20 rotating at 4°C overnight. After washing, 
the membrane was further incubated with secondary 
antibodies coupled to horseradish peroxidase at room 
temperature for 1 h and developed with an enhanced 
chemiluminescent detection kit (Amersham).
Luciferase reporter assay
The putative miR-145 binding sites at the 3’UTR 
of Twist and Sox9 were cloned downstream of a 
cytomegalovirus promoter-driven firefly luciferase cassette 
in a vector. The β-galactosidase plasmid was cotransfected 
as internal control in the presence of either synthetic miR-
145 or mock control. Luciferase reporter assay (Promega, 
Madison, WI) was performed 72 hr after transfection.
In vivo intraperitoneal metastasis model
All animal care and experimental procedures were 
carried out according to the Committee for the Use of 
Laboratory Animals of the University of Hong Kong 
approved protocols. SKOV-3 MCS (2 × 105 cells) stably 
transduced with nonspecific miRNA or pre-miR-145 were 
injected intraperitoneally into 6- to 8-week-old female 
NOD/SCID mice (Charles River Laboratories, Wilmington, 
MA) (n = 3 mice per group, and the experiment was 
conducted twice). Mice were assessed weekly for signs of 
pain and discomfort, weight change, and ascites formation. 
At the time of sacrifice, the number of all visible (> 0.1 cm 
diameter) tumor nodules in the peritoneal cavity and the 
volume of ascites were assessed as evidence of metastases.
Statistical analysis
All experiments were carried out in triplicates and 
repeated at least two times with each experiment yielding 
essentially identical results. Data are presented as mean 
± S.D. Student’s t-test and analysis of variance was 
performed in GraphPad Prism (GraphPad, San Diego, 
CA) to determine differences between the experimental 
groups and the control groups. A P-value less than 0.05 
was regarded as statistically significant.
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